Lipid nanoparticles (LNPs) are a promising platform for mRNA delivery, but their use in inflammatory pulmonary diseases is limited by reactogenicity and suboptimal delivery. Here, the authors report a VATPase activating non-inflammatory LNP (NIF-LNP) exhibiting a 40fold enhancement in lung protein expression without causing significant reactogenicity compared to commercial LNPs.
- Zhiqiang Zhao
- Xinzhu Shan
- Lei Miao
